Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

Early Phase 1

Recruiting

• Conditions: Androgenetic Alopecia (AGA)
• Interventions: Drug: Oral DHA + Topical minoxidil 5%; Drug: Topical Minoxidil 5%

• Registration Number: NCT07012486
• Lead Sponsor: Shanghai Zhongshan Hospital

Brief Summary

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is:

• Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA.

Participants will:

* Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months.

* Visit the clinic once every month for checkups and tests.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-06
• Study Start: 2025-06
• Study First Submitted: 2025-06-02
• Study First Submitted QC: 2025-06-09
• Last Update Submitted: 2025-06-09
• Study First Posted: 2025-06-10
• Last Update Posted: 2025-06-10
• Primary Completion: 2026-05
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

• Clinically diagnosed with androgenetic alopecia (AGA)
• No pregnancy plans within the next 6 months

Exclusion Criteria

• Patients who received systemic medications for hair loss within the past 2 months
• Use of topical medication for hair loss within the past 2 weeks
• Pregnancy or lactation
• Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention Arm	Oral DHA + Topical minoxidil 5%	oral dihydroartemisinin (DHA) combined with topical minoxidil
Control Arm	Topical Minoxidil 5%	topical minoxidil alone

Primary Outcome Measures

Name	Time	Method
Improvement in terminal hair follicles in the vertex area	Baseline and 180-day of treatment	Terminal hair follicles in the vertex area will be quantified before and at the end of treatment

Secondary Outcome Measures

Name	Time	Method
Change of terminal hair follicle density in the vertex area from baseline to the end of treatment	Baseline and 180-day of treatment
Change of hair density in the vertex area from baseline to the end of treatment	Baseline and 180-day of treatment
Change of terminal hair follicle density in the frontal area from baseline to the end of treatment	Baseline and 180-day of treatment	Terminal hair follicle density in the frontal area
Change of hair density in the frontal area from baseline to the end of treatment	Baseline and 180-day of treatment
Change of serum total testosterone from baseline to the end of treatment	Baseline and 180-day of treatment

Trial Locations

Locations (1)

Zhongshan Hospital Fudan University; 🇨🇳 Shanghai, Shanghai, China